Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Xingsheng Xinhui Pharmaceutical received approval from China's medical products administrator to conduct clinical trials for a colorectal cancer drug.
Specifically, the approval was for trials using XS-03 tablets in combination with FOLFOX or FOLFIRI and bevacizumab for the treating RAS-mutated metastatic colorectal cancer, according to a Thursday filing with the Shanghai bourse.
Xingsheng Xinhui plans to initiate Phase Ib/II clinical trials for this treatment regimen in mainland China once conditions are met.
Shares of the pharmaceutical company were down 1% in recent trade on the Shanghai bourse.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。